Highlands Natural Resources announced today it is collaborating up with analytical chemist Stephen Goldman to develop its cannabinoid business, Zoetic.
The company said that it is teaming up with Goldman to ‘examine, develop and file patents and other intellectual property on behalf of Company’ relating to agricultural genetics, pharmaceutical and wellness products based involving cannabinoids.
The collaboration will relate to the company’s CBD focused venture, Zoetic, which it is seeking to expand.
Back in April Highlands announced it would be advancing its strategy for the company, in light of particularly strong demand for cannabis-based products.
Robert Price, Executive Chairman and CEO of Highlands Natural Resources, said: “Our progress at Zoetic continues at pace and we remain on track to achieve our first revenues in June from deliveries to Schrader Oil convenience stores and the launch of our own direct sales website.
“Our collaboration with Stephen Goldman significantly advances our expertise in seed development and agricultural genetics and underpins our strategy to develop high quality feminised seeds for sale to hemp producers, a strategy which has significant revenue potential.”
Shares in the natural resources company (LON:HNR) are currently +3.62% as of 12:27PM (GMT).
